首页> 美国卫生研究院文献>Case Reports in Nephrology and Dialysis >Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome
【2h】

Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome

机译:肾上腺素抑制剂诱导的从头移植肾溶血性尿毒症综合征的高度敏感的肾脏同种异体移植接受者从他克莫司早期转化为贝拉西普。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundKidney transplantation is the first-line therapy for patients with end-stage renal disease since it offers greater long-term survival and improved quality of life when compared to dialysis. The advent of calcineurin inhibitor (CNI)-based maintenance immunosuppression has led to a clinically significant decline in the rate of acute rejection and better short-term graft survival rates. However, these gains have not translated into improvement in long-term graft survival. CNI-related nephrotoxicity and metabolic side effects are thought to be partly responsible for this.
机译:背景肾脏移植是终末期肾脏疾病患者的一线治疗,因为与透析相比,肾脏移植具有更高的长期生存率和更高的生活质量。基于钙调神经磷酸酶抑制剂(CNI)的维持性免疫抑制的出现已导致急性排斥反应的临床上显着下降,并且短期移植物的存活率更高。但是,这些收益并未转化为长期移植物存活的改善。 CNI相关的肾毒性和代谢副作用被认为是造成这种情况的部分原因。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号